Trials / Completed
CompletedNCT01159691
Change in Gastrointestinal Complaints After Switch From Oral Parkinson's Disease Treatment to Neupro® Transdermal Patch
A Multicentric, Non-interventional Study on Switching From Oral Parkinson Therapy to Neupro® in Patients With Idiopathic Parkinson's Disease With Gastrointestinal Symptoms
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 76 (actual)
- Sponsor
- UCB Pharma GmbH · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The study intends to collect data on gastrointestinal symptoms (swallowing disorders, heartburn, feeling of fullness, nausea, vomiting, abdominal pain, diarrhea) and on patient satisfaction under everyday practice conditions after changing treatment to Neupro® transdermal patch in patients suffering from idiopathic Parkinson´s Disease with gastrointestinal symptoms while being treated with oral antiparkinson drugs. The objective of the study is to ascertain whether switching therapy to Neupro® transdermal patch can provide any relief in gastrointestinal symptoms.
Detailed description
Routine treatment as per approved label in Europe in accordance with the terms of the local marketing authorization for Neupro®.
Conditions
Timeline
- Start date
- 2010-06-01
- Primary completion
- 2012-03-01
- Completion
- 2012-03-01
- First posted
- 2010-07-09
- Last updated
- 2013-05-21
- Results posted
- 2013-04-23
Locations
21 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT01159691. Inclusion in this directory is not an endorsement.